These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 20080852

  • 1. Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan.
    Kim WG, Ryu JS, Kim EY, Lee JH, Baek JH, Yoon JH, Hong SJ, Kim ES, Kim TY, Kim WB, Shong YK.
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1169-73. PubMed ID: 20080852
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
    Ozkan E, Aras G, Kucuk NO.
    Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
    [Abstract] [Full Text] [Related]

  • 9. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
    Trybek T, Kowalska A, Lesiak J, Młynarczyk J.
    Nucl Med Rev Cent East Eur; 2014 May; 17(2):87-93. PubMed ID: 25088108
    [Abstract] [Full Text] [Related]

  • 10. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
    Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, Rosai J, Robbins RJ.
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
    [Abstract] [Full Text] [Related]

  • 11. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
    Na SJ, Yoo IeR, O JH, Lin C, Lin Q, Kim SH, Chung SK.
    Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
    [Abstract] [Full Text] [Related]

  • 12. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
    Bannas P, Derlin T, Groth M, Apostolova I, Adam G, Mester J, Klutmann S.
    Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
    [Abstract] [Full Text] [Related]

  • 13. 18-fluorodeoxyglucose positron emission tomography in the early diagnostic workup of differentiated thyroid cancer patients with a negative post-therapeutic iodine scan and detectable thyroglobulin.
    van Dijk D, Plukker JT, Phan HT, Muller Kobold AC, van der Horst-Schrivers AN, Jansen L, Sluiter WJ, Brouwers AH, Links TP.
    Thyroid; 2013 Aug; 23(8):1003-9. PubMed ID: 23517405
    [Abstract] [Full Text] [Related]

  • 14. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging 18F-FDG PET/CT.
    Okuyucu K, Ince S, Alagoz E, Emer O, San H, Balkan E, Ayan A, Meric C, Haymana C, Acıkel C, Gunalp B, Karacalioglu AO, Arslan N.
    Hell J Nucl Med; 2016 Aug; 19(3):208-217. PubMed ID: 27824959
    [Abstract] [Full Text] [Related]

  • 15. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study.
    Koh JM, Kim ES, Ryu JS, Hong SJ, Kim WB, Shong YK.
    Clin Endocrinol (Oxf); 2003 Apr; 58(4):421-7. PubMed ID: 12641624
    [Abstract] [Full Text] [Related]

  • 16. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
    de Geus-Oei LF, Oei HY, Hennemann G, Krenning EP.
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
    [Abstract] [Full Text] [Related]

  • 17. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH, Jung DW, Pak KJ, Kim IJ, Kim HJ, Cho JK, Shin SC, Wang SG, Lee BJ.
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [Abstract] [Full Text] [Related]

  • 18. Clinical significance of observation without repeated radioiodine therapy in differentiated thyroid carcinoma patients with positive surveillance whole-body scans and negative thyroglobulin.
    Lim DJ, O JH, Kim MH, Kim JH, Kwon HS, Kim SH, Kang MI, Cha BY, Lee KW, Son HY.
    Korean J Intern Med; 2010 Dec; 25(4):408-14. PubMed ID: 21179279
    [Abstract] [Full Text] [Related]

  • 19. 18F-FDG PET/CT and ultrasonogrpahy in differentiated thyroid carcinoma patients with elevated serum levels of antithyroglobulin antibody, negative Tg and whole body 131I scan.
    Liu J, Liu B, Yu Y, Chao F, Liu Y, Han X.
    Hell J Nucl Med; 2018 Dec; 21(1):24-27. PubMed ID: 29550843
    [Abstract] [Full Text] [Related]

  • 20. Value of 18F-FDG PET negativity and Tg suppressibility as markers of prognosis in patients with elevated Tg and 131I-negative differentiated thyroid carcinoma (TENIS syndrome).
    Ranade R, Kand P, Basu S.
    Nucl Med Commun; 2015 Oct; 36(10):1014-20. PubMed ID: 26049373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.